Fort Pitt Capital Group LLC lowered its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,970 shares of the medical research company’s stock after selling 588 shares during the quarter. Fort Pitt Capital Group LLC’s holdings in Amgen were worth $15,470,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after buying an additional 3,601,087 shares during the last quarter. FMR LLC boosted its stake in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Amgen by 40.9% during the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after buying an additional 986,700 shares during the last quarter. BlackRock Inc. boosted its stake in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the last quarter. Hedge funds and other institutional investors own 78.46% of the company’s stock.
Amgen, Inc. (AMGN) opened at $181.96 on Friday. The company has a market capitalization of $132,090.00, a price-to-earnings ratio of 16.44, a price-to-earnings-growth ratio of 2.60 and a beta of 1.36. Amgen, Inc. has a fifty-two week low of $150.38 and a fifty-two week high of $191.10. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same period last year, the business posted $3.02 EPS. The business’s revenue was down .7% compared to the same quarter last year. equities analysts predict that Amgen, Inc. will post 12.71 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.90%. Amgen’s dividend payout ratio (DPR) is currently 41.55%.
Amgen announced that its board has authorized a share buyback program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.
AMGN has been the subject of several analyst reports. BMO Capital Markets reaffirmed a “market perform” rating and issued a $198.00 price objective on shares of Amgen in a research note on Thursday, October 26th. Mizuho reaffirmed a “buy” rating and issued a $198.00 price objective (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $190.15.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the sale, the executive vice president now owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock worth $1,225,765 over the last quarter. Company insiders own 0.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Fort Pitt Capital Group LLC Has $15.47 Million Stake in Amgen, Inc. (NASDAQ:AMGN)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/fort-pitt-capital-group-llc-sells-588-shares-of-amgen-inc-amgn-3.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.